Display technology on filamentous phage in the search for anti-infective biological agents

Introduction: The causes of antibiotic resistance are complex. The phage display technology has been used mainly to produce monoclonal antibodies (MAbs) and peptides directed against cancer or inflammatory disease targets. Today, this technology is recognized as a powerful tool for selecting novel p...

Full description

Bibliographic Details
Main Authors: Nelson Santiago Vispo, Frank Camacho, Maritza Pupo Antúnez, Roberto Toledo, Oliberto Sánchez Ramos
Format: Article
Language:English
Published: Universidad Católica de Oriente 2016-01-01
Series:Bionatura
Subjects:
Online Access:http://revistabionatura.com/phage-display.html
Description
Summary:Introduction: The causes of antibiotic resistance are complex. The phage display technology has been used mainly to produce monoclonal antibodies (MAbs) and peptides directed against cancer or inflammatory disease targets. Today, this technology is recognized as a powerful tool for selecting novel peptides and antibodies that can bind to a wide range of antigens, ranging from whole cells to proteins and lipid targets. In this review, we highlight research that exploits the phage display technology to discover new drugs against infectious diseases, with a focus on antimicrobial peptides and antibodies. Methods: Basic and recent literature review was made, mainly focused on general aspects of phage display technology and the application in the search of new peptides or antibodies of pharmaceutical use to combat the infectious diseases transmitted by bacteria and virus. Results: Updated information on the selected topics is shown, with a guiding and practical approach aimed at researchers in the field of molecular biology to continue deepening the technology with special emphasis in the applications that have been developed in Cuba. Conclusions: Advances in methods of screening, manufacturing, and humanization technologies show that phage display technology can significantly contribute in the fight against clinically important pathogens.
ISSN:1390-9347
1390-9355